Cartesian Therapeutics stock (RNAC) surges as the company inks a licensing deal with WestGene Biopharma to develop CAR-T cell ...
WestGene’s established targeted LNP platform combined with Cartesian’s mRNA payload from Descartes-08 integrates two independently, clinically ...
Shares of Cartesian Therapeutics rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune ...
Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.
WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans ...
Cartesian Therapeutics, Inc. RNAC stock is up on Tuesday as the company is announcing a strategic licensing agreement with ...
At the time of writing, FAC stock was up nearly 40% premarket and was among the top-trending tickers on Stocktwits. Factorial ...
The company said it expects to sell 25 million units at $10 each, with each unit consisting of one share and one warrant to buy an additional share for $11.50. It expects to list its shares on Nasdaq ...
Factorial Energy ( (FAC) ) just unveiled an announcement.
GlobalData on MSN
Factorial Energy goes public at $1.3bn valuation after SPAC merger
Mercedes-Benz, Stellantis, Hyundai, and Kia are among the company’s backers, along with In-Q-Tel, which was set up by the CIA ...
Factorial Energy (FAC) stock surged post-SPAC on low float hype, but revenue is years away and dilution risk looms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results